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Purpose: To report clinical efficacy, predictors of success, and safety of primary selective laser trabeculo-
plasty (SLT) used in treatment-naive patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Design: Post hoc analysis of a multicenter, prospective, randomized, controlled trial.
Participants: Treatment-naive patients with OAG or OHT.
Methods: Patients randomized to SLT or topical medication and treated to predefined target intraocular
pressures (IOPs) requiring 20% IOP reduction from baseline for all disease severity levels.
Outcome Measures: Initial (early) absolute IOP-lowering at 2 months. Achievement of drop-free disease-
control: meeting target IOP without disease progression or need for additional topical medication over 36 months
after SLT. Predictors of early absolute IOP-lowering and drop-free disease-control after single initial SLT. Fre-
quency of laser-related complications.
Results: A total of 611 eyes (195 OHT and 416 OAG) of 355 patients received SLT, and 622 eyes (185 OHT
and 437 OAG) of 362 patients received topical medication at baseline. Early absolute IOP-lowering after SLT was
no different between OHT and OAG eyes (adjusted mean difference ¼ 0.05 mmHg; 95% confidence interval
[CI], 0.6 to 0.5 mmHg; P ¼ 0.85). No difference was noted in early absolute IOP-lowering between topical
medication and primary SLT (adjusted mean difference ¼ 0.1 mmHg; 95% CI, 0.6 to 0.4 mmHg; P ¼ 0.67).
Early absolute IOP-lowering with primary SLT was positively associated with baseline IOP (coefficient 0.58; 95%
CI, 0.53e0.63; P < 0.001) and negatively with female gender (coefficient 0.63; 95% CI, 1.23 to 0.02; P ¼
0.04). At 36 months, 536 eyes (87.7% of 611 eyes) of 314 patients (88.5% of 355 patients) were available for
analysis. Some 74.6% of eyes (400 eyes) treated with primary SLT achieved drop-free disease-control at 36
months; 58.2% (312 eyes) after single SLT. Total SLT power and 2-month IOP were predictors of drop-free
disease-control at 36 months after single SLT. Six eyes of 6 patients experienced immediate post-laser IOP
spike (>5 mmHg from pretreatment IOP) with 1 eye requiring treatment.
Conclusions: Primary SLT achieved comparable early absolute IOP-lowering in OHT versus OAG eyes.
Drop-free disease-control was achieved in approximately 75% eyes at 36 months after 1 or 2 SLTs, the majority
of these after single SLT. These analyses are exploratory but support primary SLT to be effective and safe in
treatment-naive OAG and OHT eyes. Ophthalmology 2019;126:1238-1248 Crown Copyrightª 2019 Published by
Elsevier Inc. on behalf of the American Academy of Ophthalmology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.Over the past 2 decades, selective laser trabeculoplasty
(SLT) has become an established treatment to lower intra-
ocular pressure (IOP) for open-angle glaucoma (OAG) and
ocular hypertension (OHT). Introduced by Latina and Park
in 1995, SLT uses a 532 nm Q switched, frequency-doubled1238 Crown Copyright ª 2019 Published by Elsevier Inc. on behalf of the Ame
Academy of Ophthalmology. This is an open access article under the CC
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).neodymium-doped yttrium aluminum garnet (Nd:YAG)
laser that delivers a short pulse duration (3 ns)1 to reduce
IOP by increasing aqueous outflow through the trabecular
meshwork (TM).2 The procedure is short and outpatient-
based, with quick recovery and good safety profile.3rican
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Table 1. Severity Criteria for Setting Treatment Target Intraocular Pressure from the “Canadian Target IOP Workshop” (with Central
Field Criteria Defined According to Mills)
Severity
Definition of Severity for Treatment Target IOP
Optic Nerve VF MD Central (10o) Scotoma on VF
OHT Healthy Any No GON-related VFL
Mild OAG GON þ >6 dB þ None
Moderate OAG GON þ 6 dB< and
>12 dB
or At least 1 central 5 point
<15 dB but none <0 dB and only 1 hemifield with
central point <15 dB
Severe OAG GON þ <12 dB or Any central 5 point with sensitivity <0 dB
Both hemifields contain point(s) <15 dB within
5 of fixation
dB ¼ decibels; IOP ¼ intraocular pressure; GON ¼ glaucoma optic neuropathy; OAG¼ open-angle glaucoma; VF ¼ visual field; VFL¼ visual field loss; VF
MD ¼ visual field mean deviation.
Table 2. Setting Treatment Target Intraocular Pressure
Baseline Disease Severity Treatment Target IOP
OHT >20% IOP reduction from baseline IOP or
IOP <25 mmHg (whichever lower)
Mild OAG >20% IOP reduction from baseline IOP or
IOP <21 mmHg (whichever lower)
Moderate OAG >30% IOP reduction from baseline IOP or
IOP <18 mmHg (whichever lower)
Severe OAG >30% IOP reduction from baseline IOP or
IOP <15 mmHg (whichever lower)
IOP ¼ intraocular pressure; OAG ¼ open-angle glaucoma; OHT ¼ ocular
hypertension.
Garg et al  SLT in Treatment-Naive Patients with OAG and OHTSelective laser trabeculoplasty has the potential advantage of
avoiding issues associated with topical IOP-lowering med-
ications, such as local and systemic side effects and variable
patient adherence. Since Food and Drug Administration
approval in 2001, SLT increasingly has been adopted into
practice. In the United States, 75 647 trabeculoplasties were
performed in 2001, and this increased to 142 682 procedures
in 2012.4
Studies investigating SLT as a primary treatment have
found a similar IOP-lowering efficacy and success rate to
topical medication using various success criteria.3 However,
several of these studies include patients taking IOP-lowering
topical medications that were stopped for a variable duration
before receiving SLT.5-8 Despite a washout period to miti-
gate against residual effects of prior topical treatment, SLT
can be less effective after topical treatment.6 Few studies
have evaluated primary SLT in true treatment-naive
patients,9-11 and there is limited knowledge of predictors
of IOP-lowering response, treatment success, and safety in
such patients.
The Laser in Glaucoma and Ocular Hypertension
(LiGHT) Trial was a multicenter randomized controlled trial
(RCT) conducted to establish whether initial treatment with
SLT is superior to initial treatment with medication for
treatment-naive patients with OAG or OHT in relation to
health-related quality of life (HRQL), cost-effectiveness,
and clinical efficacy at 36 months.12 Eyes in the primary
SLT arm were at target IOP over more clinical visits
during 36-month follow-up compared with drops, with
fewer eyes demonstrating disease progression and fewer
cataract and trabeculectomy surgeries. Primary SLT was
found to be more cost-effective than initial medication over
the course of 36 months, despite a lack of HRQL differences
between the 2 arms.13
This report characterizes the IOP-lowering, drop-free
disease-control and safety achieved by primary SLT in
treatment-naive patients with OAG and OHT as part of
LiGHT, in which eyes were treated to predefined target IOP
on the basis of disease severity. We also investigated pre-
dictors of initial (early) IOP lowering and predictors for
achieving drop-free disease-control at 36 months after single
initial SLT. We hypothesized that primary SLT would
demonstrate effective IOP lowering in treatment-naive OHTand OAG eyes with a comparable effect to topical medi-
cation. We anticipated that absolute IOP lowering could be
greater in OHT versus OAG eyes because of higher pre-
treatment baseline IOPs and that drop-free disease-control
would be more readily achieved in eyes with less-advanced
disease because target IOPs were higher.Methods
The study was conducted in accordance to Good Clinical
Practice guidelines and adhered to the tenets of the Declaration
of Helsinki. Institutional Review Board/Ethics Committee
approval was obtained. All patients provided written informed
consent before participation in the trial. The LiGHT Trial
is registered at www.controlled-trials.com (registration number
ISRCTN32038223).
This study was a post hoc analysis of the LiGHT trial, the
design and baseline characteristics of which have been
described.12,14 Briefly, consecutive eligible patients were identified
at the clinics of 6 participating centers in the United Kingdom from
October 2012 to October 2014. Eligible patients had newly diag-
nosed, untreated OAG or OHT in 1 or both eyes and qualified for
treatment according to National Institute of Clinical Excellence
guidelines,15 open angles on gonioscopy, visual field loss with
mean deviation (VF MD) not worse than 12 decibels (dB) in
the better eye or 15 dB in the worse eye, and, for OAG,
corresponding damage to the optic nerve head. Patients were
18 years or older and able to read and understand English
and had a visual acuity of 20/120 or better in the treated eye(s)1239
Table 3. Baseline Characteristics of Primary Selective Laser
Trabeculoplasty Arm
Characteristics Value
Age (yrs), mean (SD) 63.4 (12.1)
Gender (patients), (%)
Male 199 (56.1%)
Female 156 (43.9%)
Race/ethnicity (patients), (%)
White European 242 (68.2%)
Black 77 (21.7%)
Asian 23 (6.5%)
Other 13 (3.7%)
Laterality (patients), (%)
Bilateral eyes 256 (72.1%)
Right eye 49 (13.8%)
Left eye 50 (14.1%)
Hypertension (patients), (%)
Yes 131 (36.9%)
No 224 (63.1%)
Diabetes mellitus (patients), (%)
Yes 41 (11.6%)
No 314 (88.5%)
Disease severity (eyes), (%)
OHT 195 (31.9%)
Mild OAG 309 (50.6%)
Moderate OAG 67 (11.0%)
Severe OAG 40 (6.5%)
Mean deviation (dB), mean (SD) 3.0 (3.4)
Pattern SD (dB), mean (SD) 3.7 (2.9)
Mean HRT area (mm2), mean (SD) 1.2 (0.4)
Baseline IOP (mmHg), mean (SD)
Overall 24.5 (5.2)
OHT 26.5 (3.5)
OAG 23.5 (5.6)
Average trabecular pigmentation grade (eyes), (%)
0- None 243 (39.8%)
1- Mild 264 (43.2%)
2- Moderate 101 (16.5%)
3- Dense 1 (0.2%)
Unknown 2 (0.4%)
Habitual VA (logMAR), mean (SD) 0.10 (0.2)
CCT (mm), mean (SD) 550.6 (38.1)
PXF (eyes), (%)
Yes 5 (0.8%)
No 606 (99.2%)
Target IOP (mmHg)
OHT 21.1 (2.4)
Mild OAG 17.9 (3.1)
Moderate OAG 15.9 (2.6)
Severe OAG 13.9 (1.6)
CCT ¼ central corneal thickness; dB ¼ decibels; HRT ¼ Heidelberg
Retina Tomography; IOP ¼ intraocular pressure; logMAR ¼ logarithm of
the minimum angle of resolution; OAG ¼ open-angle glaucoma; OHT ¼
ocular hypertension; PXF ¼ pseudoexfoliation; SD ¼ standard deviation;
VA ¼ visual acuity. Self-defined ethnicity; Asian ethnicity refers to Indian,
Pakistani, Bangladeshi, and any other Asian background, black ethnicity
refers to Caribbean, African, and any other black background, Other
ethnicity refers to Chinese and any other ethnic groups.
Ophthalmology Volume 126, Number 9, September 2019and no previous intraocular surgery, except uncomplicated
phacoemulsification at least 1 year before entering the trial.
Patients were excluded if there were any contraindications to
SLT, they were unable to use topical medical therapy, they had
visually symptomatic cataract and wanted to undergo cataract
surgery, or they were receiving active treatment for another1240ophthalmic condition. Patients with 1 or both eyes eligible were
treated. All measurements influencing treatment escalation
decisionsdautomated visual field using Humphrey Field
Analyzer Mark II Swedish interactive threshold algorithm
standard 24-2 program (Carl Zeiss Meditec, Dublin, CA),
Heidelberg Retina Tomography disc imaging (Heidelberg
Engineering, Heidelberg, Germany), and IOP (Goldmann
applanation tonometry with daily calibration verification)dwere
performed by masked observers. Patients were monitored for 3
years. Disease category and severity were defined using preset
objective severity criteria from the Canadian Target IOP
Workshop16 with additional central VF loss criteria17 (Table 1).
Severity stratification (OHT, mild, moderate, or severe OAG)
determined an eye-specific “Target IOP” and follow-up intervals.
Target IOP was objectively defined using both percentage reduction
from untreated IOP and an absolute value, with the final target IOP
being the lower of the 2 values (Table 2). Achievement of target IOP
thus required aminimum IOP reduction of>20% from baseline IOP,
irrespective of disease severity.
Standardized criteria to escalate treatment were used according
to a protocol following international guidelines by the European
Glaucoma Society,18 American Academy of Ophthalmology
Preferred Practice Pattern,19 and the South-East Asia Glaucoma
Interest Group.20 These were incorporated into a real-time web-
based clinical decision support software, based on optic disc
analysis (Heidelberg Retina Tomography), automated visual fields
analysis (Humphrey Visual Field) and IOP measurements. Criteria
for defining IOP not at target and disease progression by Heidel-
berg Retina Tomography and VF have been reported.12
Standardization of SLT deliverywas achieved by protocol-defined
settings and clinical end points. The protocol advised 360-degree TM
treatment, 100 nonoverlapping shots (25 per quadrant) of a preset 3
nanoseconds duration and preset 400 mm spot size, with the laser
energy varied from 0.3 to 1.9 mJ by the clinician according to just
observable bubble formation. Intraocular pressure was checked 60
minutes after SLT procedure. One SLT re-treatment was permitted
during the study, if/when a treatment escalation was recommended by
the decision support software and confirmed by the treating clinician.
To allow time for the full effects of laser to occur, the earliest interval at
which repeat SLT was permitted was after the first scheduled visit 2
months after initial SLT. Selective laser trabeculoplasty was not
repeated if significant complications of laser treatment occurred, if
there was a lack of IOP-lowering response after initial SLT (judged by
the treating cliniciane not protocol defined), or if other new medical
conditions prevented repetition. In such cases, treatment escalation
with topical medication rather than repeat SLT was permitted. In eyes
that underwent repeat SLT, if further treatment escalation was
required, the next step was topical medication. The earliest planned
interval at which this could be initiated was after the first scheduled
visit 2 months after repeat SLT.
Follow-up intervals were initially set at entry to the study ac-
cording to National Institute of Clinical Excellence guidance21 and
subsequently adjusted on the basis of IOP control, glaucoma
progression, or adverse reactions. The routine schedule of
appointments and assessments for patients has been published
previously.14 At follow-up, patients underwent visual acuity
testing (Early Treatment Diabetic Retinopathy Study logarithm of
the minimum angle of resolution), slit-lamp examination, visual
field testing (Humphrey Field Analyzer Mark II SITA standard 24-
2), Heidelberg Retina Tomography optic disc imaging, IOP mea-
surement (Goldmann applanation tonometry), and clinical assess-
ment of the optic discs, maculae, and fundi.
To investigate the IOP-lowering efficacy of primary SLT for
OHT versus OAG, we evaluated the initial (early) absolute IOP
reduction at 2 months for all eyes receiving primary SLT. This was
the first scheduled visit (after safety IOP check visit at 2 weeks
Figure 1. Scatter plot of absolute intraocular pressure (IOP) reduction versus baseline IOP in all eyes (559 eyes) at 2 months after initial SLT. Filled circles:
ocular hypertension (OHT). Hollow circles: open-angle glaucoma (OAG).
Garg et al  SLT in Treatment-Naive Patients with OAG and OHTpost-laser) after laser at baseline. To contextualize the early IOP-
lowering efficacy of primary SLT in treatment-naive eyes, we
compared early absolute IOP reduction at 2 months after primary
SLT with 2-month absolute IOP reduction in eyes from the
Medication-1st arm of the LiGHT trial that had commenced topical
medication at baseline. To investigate if early absolute IOP
lowering after primary SLT was predicted by clinically relevant
baseline factors, a linear regression analysis was performed (see
“Statistical Methods”).
The LiGHT trial followed a “Treat in Pursuit of Control”
design, and thus, after the first scheduled visit at 2 months, the
web-based clinical decision support software began to monitor and
escalate treatment (if required) for each eye based on achievement
of disease control, that is, achievement of predefined target IOP
with no objective evidence of disease progression. Eyes with OAG
had lower predefined target IOPs than OHT eyes (Table 2) and thus
were more likely to require greater treatment intensity compared
with OHT eyes to achieve disease control. Intraocular pressure
comparisons between OHT and OAG eyes at later time points
would be confounded by differences in treatment intensity and
were not performed.
We evaluated treatment intensity of primary SLT in OHT
versus OAG eyes by assessment of drop-free disease-control
achieved by primary SLT at 12, 24, and 36 months. The LiGHT
treatment protocol permitted a single SLT retreatment (if required);
therefore, we determined drop-free disease-control achieved by 1
or 2 SLTs collectively and by initial, single SLT alone.
In the SLT literature, the most commonly defined measure of
success is a minimum IOP reduction of 20% from baseline IOP
after SLT at a specified time point, without the need for further
intervention.22 In LiGHT, the predefined target IOPs required a
minimum IOP reduction of >20% from baseline IOP for all
disease severities (Table 2); thus, eyes achieving drop-freedisease-control at 36 months after a single, initial SLT would
serve as a useful (although more stringent) success comparator
with preexisting SLT studies. A logistic regression analysis of
factors to predict eyes achieving drop-free disease-control at 36
months after initial, single SLT was performed. To determine the
safety of primary SLT, the frequency of laser-related complications
and adverse events over 36 months was collated.Statistical Methods
The sample size for LiGHT was based on analyses planned to
assess HRQL in treatment-naive patients with OAG/OHT treated
initially with primary SLT or topical medication. The sample size
was 718 patients, calculated to detect a difference of 0.05 in EQ-
5D-5L between the 2 arms at 36 months using a 2-sample t test
at the 5% significance level with 90% power, assuming a common
standard deviation (SD) of 0.1923 and 15% attrition.
In this report, the unit of analysis was the eye. All eligible study
eyes that received SLT at baseline were included in the analysis
with appropriate measures taken to account for correlation among
paired eyes within a subject.
Summary statistics of the demographic and clinical character-
istics are presented for all eligible study eyes. Descriptive statistics
are presented as means and SDs. Analysis comparing baseline
demographics of eyes available to those unavailable to analyze at
36 months was performed. The t test or Wilcoxon rank-sum test
was used for comparison of continuous data, and chi-square test
was used for categoric data.
To compare absolute IOP reduction at 2 months between OHT
and OAG eyes, a mixed-effects model using the eye as the unit of
analysis and using patients as a random factor to adjust for cor-
relation between paired eyes was performed. The model also1241
Table 4. Univariable Linear Regression Analysis for Absolute
Intraocular Pressure Reduction
Variable Coefficient 95% CI P Value
Baseline IOP (mmHg) 0.59 (0.54e0.64) <0.001*
Race/ethnicity 0.17
Black 1.18 (0.08e2.29)
Asian 0.89 (0.87 to 2.66)
Other 0.70 (1.75 to 3.15)
*Reference white
European
Sex
Female 1.42 (2.29 to 0.54) 0.002*
Age (yrs) 0.04 (0.08 to 0.00) 0.05*
CCT (mm) 0.01 (0.00e0.02) 0.15
PXF (Y/N)
No 1.62 (4.94 to 1.69) 0.34
Average TM Pigmentation
grade
0.12
1- Mild 0.12 (1.04 to 0.81)
2- Moderate 0.03 (1.16 to 1.23)
3- Dense 6.51 (1.06e12.0)
*Reference no
pigmentation
Phakic status (Y/N)
Phakic 0.70 (0.90 to 2.29) 0.39
Hypertension (Y/N)
No 0.05 (0.87 to 0.96) 0.92
Diabetes mellitus (Y/N)
No 0.82 (0.51 to 2.15) 0.22
Total power 1st SLT (mJ) 0.01 (0.01 to 0.03) 0.29
Total No. of shots 1st SLT
(shots)
0.04 (0.03 to 0.11) 0.26
CCT ¼ central corneal thickness; CI ¼ confidence interval; IOP ¼
intraocular pressure; PXF ¼ pseudoexfoliation; SLT ¼ selective laser tra-
beculoplasty; TM ¼ trabecular meshwork.
*Covariates that achieved P < 0.10 in the initial variable selection linear
regression analyses were baseline IOP (P< 0.001), gender (P ¼ 0.002), and
age (P ¼ 0.05).
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control for center effects in a multicenter trial). To compare ab-
solute IOP reduction at 2 months between primary SLT versus
topical medication, a similar mixed-effects model was also used.
To examine baseline predictors of early absolute IOP reduction
at 2 months in eyes receiving primary SLT, univariate mixed effect
linear regression analyses were performed using the eye as the unit
of analysis and using patients as a random factor to adjust for
correlation between paired eyes. Patient-related baseline charac-
teristics considered for univariable selection were age, gender,
ethnicity, phakic status, baseline IOP, central corneal thickness,
TM pigmentation, pseudoexfoliation, hypertension, and diabetes
mellitus. Laser-related characteristics included total SLT power
and total number of SLT shots of initial SLT at baseline.Table 5. Multivariable Linear Regression Analysis for Absolute
Intraocular Pressure Reduction
Variable Coefficient 95% CI P Value
Baseline IOP (mmHg) 0.58 (0.53e0.63) <0.001
Sex
Female
0.63 (1.23 to 0.02) 0.04
CI ¼ confidence in interval; IOP ¼ intraocular pressure.
1242Covariates that achieved P < 0.10 in the univariable selection
regression analyses were entered in a mixed-effect multivariable
linear regression model controlling for LiGHT stratification factors
(disease severity and treating center). The regression model was
then run, with nonsignificant variables removed one by one until
only significant (P < 0.05) variables remained.
A similar approach involving logistic regression was used to look
for predictors of drop-free disease-control at 36 months. For the lo-
gistic regression analysis, a success criterion defined as eyes that
achieved drop-free disease-control after initial, single SLT at base-
line was used. This was a more stringent criterion than used else-
where. We also considered the 2-month IOP to assess if this was a
posttreatment predictor of drop-free disease-control at 36 months.
Statistical significance was defined as a 2-sided P value < 0.05.
Analyses were carried out using Stata15 (Stata Statistical Software:
Release 15, 2015; StataCorp LP, College Station, TX).
Results
A total of 356 patients (613 eyes) were randomized to the Laser 1st
arm of LiGHT. One patient (2 eyes) withdrew consent before
receiving SLT at the baseline visit; thus, 355 patients (611 eyes)
received primary SLT. At 36 months, 536 eyes of 314 patients
were available for analysis. Of the 75 remaining eyes, 22 eyes (of
13 patients) were formally lost to follow-up (withdrew, died,
illness, or moved) during the course of the 3-year trial. The
remaining 53 eyes (of 28 patients) were still returning HRQL
questionnaires in the main LiGHT study, but clinical data were not
available at the 36-month time-point. Analysis comparing baseline
demographics of eyes available versus unavailable to analyze at 36
months (536 vs. 77 eyes) demonstrated no clinically or statistically
significant differences in age, baseline IOP, ethnicity, gender,
disease severity, and VF mean deviation. A statistically but not
clinically significant difference in baseline visual acuity was noted
between groups (mean difference logarithm of the minimum angle
of resolution 0.06; 95% CI, 0.1 to 0.01; P ¼ 0.02) (Appendix
2, available at www.aaojournal.org).
Baseline Characteristics
Baseline demographic data of the 611 eyes are shown in Table 3.
There was a greater proportion of male patients than female
patients (56.1% vs. 43.9%) at baseline. The most common
ethnicities were white European (68.2%) and black (21.7%).
Some 72.1% of patients had both eyes in the study, 13.8% had
only the right eye, and 14.1% had only the left eye in the study;
31.9% of eyes had a diagnosis of OHT (195 eyes) compared
with 68.1% of eyes with OAG (416 eyes). This is reflected in
the average mean deviation (MD) value of 3.0 dB. Mean
baseline IOP was 24.5 mmHg (SD, 5.2) for all eyes but was
greater in OHT eyes (26.5 mmHg; SD, 3.5) than in OAG eyes
(23.5 mmHg; SD, 5.6). During initial SLT, mean total power
delivered was 90.4 (SD, 23.5) mJ via a mean treatment of 99.2
(SD, 5.1) shots. Baseline demographic data of the 622 eyes in
the Medication 1st arm is also provided (Appendix 3, available
at www.aaojournal.org).
Early Intraocular PressureeLowering Efficacy of
Primary Selective Laser Trabeculoplasty
A total of 559 eyes (of 611 eyes at baseline) were available for
analysis at the 2-month time point in the primary SLT arm having
undergone initial SLT at baseline (Fig 1). Mean initial IOP
lowering at 2 months was 8 mmHg (SD, 4.0) in OHT eyes and
6.5 mmHg (SD, 4.3) in OAG eyes. Mean percentage IOP
Table 6. Eyes Achieving Drop-free Disease-Control Using 1 or 2 Selective Laser Trabeculoplasties
Disease Severity
12 mos Total
Eyes Available for
Analysis (n)
12 mos Eyes
Achieving Drop-free
Disease Control % (n)
24 mos Total Eyes
Available for
Analysis (n)
24 mos Eyes
Achieving Drop-free
Disease Control % (n)
36 mos Total
Eyes Available for
Analysis (n)
36 mos
Eyes Achieving
Drop-Free
Disease Control
% (n)
All eyes 608 85.2% (518) 576 79.2% (456) 536 74.6% (400)*
OHT 192 92.7% (178) 174 92% (160) 158 88.6% (140)
Mild OAG 315 87.3% (275) 293 81.2% (238) 269 76.6% (206)
Moderate OAG 54 63% (34) 69 56.5% (39) 57 56.1% (32)
Severe OAG 47 65.9% (31) 40 47.5% (19) 52 42.3% (22)
OAG ¼ open-angle glaucoma; OHT ¼ ocular hypertension.
*One eye was protocol deviation and received 3 selective laser trabeculoplasties.
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14.7) in OAG eyes, respectively. A clear trend was noted toward
increasing absolute IOP reduction with higher baseline IOP in
both OHT and OAG eyes (Fig 1), but there was no significant
difference in early absolute IOP lowering between OHT and
OAG eyes having controlled for pretreatment baseline IOP and
center effects (adjusted mean difference ¼ 0.05 mmHg; 95%
confidence interval [CI], 0.6 to 0.5 mmHg; P ¼ 0.85).
For comparison, 594 eyes (of 622 eyes at baseline) were
available for analysis in the Medication 1st arm at 2 months. Of
these, 99.3% (590 eyes) were receiving a single medication (96.1%
were receiving topical prostaglandin, 1.9% were receiving a b-
blocker, 0.3% were receiving a carbonic anhydrase inhibitor, 0.3%
were receiving an alpha agonist, and 0.7% were receiving 2
medications). Mean initial IOP lowering at 2 months was 7.6
mmHg (SD, 4) in OHT eyes and 6.8 mmHg (SD, 4.4) in OAG
eyes. Mean (SD) percentage IOP reduction was 27.9% (13.5) in
OHT eyes and 27.9% (14.4) in OAG eyes, respectively.
Overall, absolute IOP reduction at 2 months was no different
between topical medication and primary SLT (adjusted mean
difference ¼ 0.1 mmHg; CI, 0.6 to 0.4 mmHg; P ¼ 0.67).
There was no difference in absolute IOP reduction for OHT eyes
(adjusted mean difference ¼ 0.4 mmHg; CI, 0.4 to 1.2 mmHg;
P ¼ 0.31) or OAG eyes (adjusted mean difference ¼ 0.2 mmHg;
CI, 0.8 to 0.3 mmHg; P ¼ 0.36) between the 2 treatment groups.
Predictors of Early Intraocular
PressureeLowering Response after Primary
Selective Laser Trabeculoplasty
For the predictors of initial IOP-lowering response, covariates that
achieved P < 0.10 in the initial variable selection regressionTable 7. Eyes Achieving Drop-free Disease-Control after Si
Disease Severity
12 mos
Total Eyes
Available for
Analysis (n)
12 mos
Eyes Achieving Drop-free
Disease Control
after Single SLT % (n)
24 mos
Total Eyes
Available for
Analysis (n)
E
All eyes 608 75.5% (459) 576
OHT 192 85.9% (165) 174
Mild OAG 315 79.4% (250) 293
Moderate OAG 54 46.3% (25) 69
Severe OAG 47 40.4% (19) 40
OHT ¼ ocular hypertension; OAG ¼ open-angle glaucoma; SLT ¼ selectiveanalyses were baseline IOP (P < 0.001), gender (P ¼ 0.002), and
age (P ¼ 0.05) (Table 4). Within-group (OHT vs. OAG) sub-
analysis demonstrated that the trend noted toward increasing ab-
solute IOP reduction with higher baseline IOP (Fig 1) was
significant in both OHT (coefficient 0.68; 95% CI, 0.55e0.81; P
< 0.001) and OAG (coefficient 0.58; 95% CI, 0.53e0.64; P <
0.001). The final multivariable linear regression model showed
that baseline IOP (P < 0.001) and gender (P ¼ 0.04) were
predictors of initial absolute IOP reduction (Table 5).
Drop-Free Disease Control
Eyes that met target IOP without disease progression or need for
topical IOP-lowering medication were deemed to have achieved
drop-free disease-control. At 12 months, 85.2% of eyes (518 eyes)
achieved drop-free disease-control after 1 or 2 SLTs. At 24 months
and 36 months, 79.2% of eyes (456 eyes) and 74.6% of eyes (400
eyes), respectively, continued to achieve drop-free disease-control
(Table 6). At all time points, drop-free disease-control was ach-
ieved in a higher percentage of OHT and mild OAG eyes compared
with moderate and severe OAG eyes.
Drop-Free Disease Control after Initial Single
Selective Laser Trabeculoplasty
Assessing drop-free disease-control achieved by initial single SLT
at baseline, 75.5% of eyes (459 eyes) achieved this at 12 months,
66.5% of eyes (383 eyes) achieved this at 24 months, and 58.2% of
eyes (312 eyes) achieved this at 36 months. At all time points,
drop-free disease-control after single initial SLT was achieved in a
higher percentage of OHT and mild OAG eyes compared with
moderate and severe OAG eyes (Table 7).ngle, Initial Selective Laser Trabeculoplasty at Baseline
24 mos
yes Achieving Drop-free
Disease Control
after Single SLT % (n)
36 mos
Total Eyes Available
for Analysis (n)
36 mos Eyes
Achieving Drop-free
Disease Control
after Single SLT % (n)
66.5% (383) 536 58.2% (312)
80.5% (140) 158 72.8% (115)
70.6% (207) 269 64.3% (173)
42% (29) 57 33.3% (19)
17.5% (7) 52 9.6% (5)
laser trabeculoplasty.
1243
Table 8. Mean Intraocular Pressure Reduction and Percentage Intraocular Pressure Reduction at 36 Months in Eyes Achieving Drop-free
Disease-Control after Single Initial Selective Laser Trabeculoplasty
Drop-free
Disease Control
Using Single SLT at
36 mos (Eyes)
Mean (SD)
Absolute IOP
Reduction (mmHg)
Mean (SD) %
IOP Reduction
from Baseline
All eyes 312 8.1 (4.1) 31.4 (11.7)
OHT 115 8.8 (3.6) 32.7 (11.5)
Mild OAG 173 7.5 (4.3) 29.9 (11.7)
Moderate OAG 19 8.6 (3.9) 36.4 (11.7)
Severe OAG 5 8.2 (4.6) 34.4 (13.1)
IOP ¼ intraocular pressure; OAG ¼ open-angle glaucoma; OHT ¼ ocular hypertension; SD ¼ standard deviation; SLT ¼ selective laser trabeculoplasty.
Table 9. Univariable Selection Logistic Regression Analysis
Variable Odds Ratio 95% CI P Value
Baseline IOP (mmHg) 1.01 (0.95e1.09) 0.69
Race/ethnicity 0.74
Black 1.55 (0.57e4.20)
Asian 0.74 (0.16e3.41)
Other 1.78 (0.23e13.64)
*Reference white European
Sex
Female 0.57 (0.26e1.28) 0.17
Age (yrs) 0.97 (0.94e1.00) 0.09*
CCT (mm) 1.00 (0.99e1.01) 0.62
PXF status
Nil PXF 18.9 (0.28e1294.66) 0.17
Average TM Pigmentation grade 0.98
1- Mild 1.1 (0.47e2.57)
2- Moderate 1.1 (0.34e3.26)
3- Dense 1y
*Reference no pigmentation
Phakic status
Phakic 0.52 (0.10e2.67) 0.44
Hypertension (Y/N)
No 0.63 (0.28e1.43) 0.27
Diabetes mellitus (Y/N)
No 1.07 (0.30e3.80) 0.91
Total power 1st SLT (mJ) 1.01 (1.00e1.03) 0.08*
Total No. of shots 1st SLT (shots) 1.02 (0.96e1.10) 0.41
2-mo IOP post-treatment (mmHg) 0.71 (0.61e0.82) <0.001*
CCT ¼ central corneal thickness; CI ¼ confidence interval; IOP ¼
intraocular pressure; PXF ¼ pseudoexfoliation; SLT ¼ selective laser tra-
beculoplasty; TM ¼ trabecular meshwork.
*Covariates that achieved P < 0.10 in the initial variable selection logistic
regression analyses were total power of 1st SLT (P ¼ 0.08) and age (P ¼
0.09).
yModel unable to converge because of insufficient data.
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eyes achieving drop-free disease-control after single initial SLT at
baseline was 8.1 mmHg (SD, 4.1). Mean absolute IOP reduction
was similar between all disease severities (Table 8).
By 36 months, 23 eyes had objective evidence of disease pro-
gression (19 eyes visual field progression, 2 eyes had disc pro-
gression, 2 eyes had disc and VF progression), and 26 eyes had an
upward revision of target IOP, if IOP control was not initially
achieved in the absence of disease progression.12 These results
account for this, such that all eyes achieving drop-free disease-
control met target IOP (achieving >20% IOP reduction from
baseline IOP) without disease progression or need for topical
medication. This is reflected in the number of eyes achieving drop-
free disease-control at 36 months (74.6% eyes) and after single
initial SLT (58.2% eyes) being slightly fewer compared with those
solely achieving target IOP without topical medication at 36
months (78.2% eyes) and after single initial SLT (59.9%) as re-
ported in the LiGHT main outcomes article.13
Predictors of Drop-Free Disease Control at 36
Months
A total of 312 eyes achieved drop-free disease-control at 36 months
after initial single SLT (Table 8). These eyes achieved >20% IOP
reduction from baseline IOP and thus were a treatment success
(using conventional “IOP lowering >20% from baseline IOP”
definition of success). Baseline covariates that achieved P < 0.10
in the mixed-effects univariable logistic regression analyses were
total power of 1st SLT (P ¼ 0.08) and age (P ¼ 0.09) (Table 9).
Two-month IOP (P < 0.001) was a posttreatment covariate that
achieved P < 0.10 in the univariable logistic regression analysis.
The final mixed-effects multivariable logistic regression model of
baseline factors showed that total power of first SLT (Table 10)
was a predictor of achieving drop-free disease-control at 36
months after single initial SLT (adjusted odds ratio, 1.02; 95% CI,
1.01e1.04; P ¼ 0.01). Two-month IOP was also a posttreatment
predictor of drop-free disease-control at 36 months when control-
ling for the other significant baseline factors (adjusted odds ratio,
0.66; 95% CI, 0.57e0.79; P < 0.001) (Table 10).
Selective Laser Trabeculoplasty Safety
There were no sight-threatening adverse events related to primary
SLT during or after the procedure (Table 11). Six eyes (of 6
patients) experienced immediate post-laser IOP spike (>5 mmHg
from pretreatment IOP) at 60 minutes, but only 1 of these eyes
required medical treatment. No IOP spikes >10 mmHg from
pretreatment IOP at 60 minutes postprocedure were reported. In 4
patients (1.1%), there was difficulty in visualizing the angle, and in12443 patients (0.9%), fewer laser applications than required by the
protocol were reported to have been used. After SLT, symptoms
including ocular discomfort, headache, blurred vision, and photo-
phobia were reported by 34.4% of patients (122 patients). These
were of a transient nature and self-limiting; all had resolved by the
first scheduled visit. No IOP spikes (>5 mmHg from baseline IOP)
were detected at the 2-week safety check visit post-SLT; 6.2% of
eyes (38 eyes) were noted to have a higher IOP at 2-week safety
visit compared with baseline.
Table 10. Multivariable Logistic Regression Analysis Result of
Baseline Factors
Variable Odds Ratio 95% CI P value
Total power 1st SLT (mJ) 1.02 (1.01e1.04) 0.01
*2-mo IOP post-treatment (mmHg) 0.66 (0.57e0.79) <0.001
CI ¼ confidence interval; IOP ¼ intraocular pressure; SLT¼ selective laser
trabeculoplasty.
*Two-month IOP is a posttreatment predictor.
Garg et al  SLT in Treatment-Naive Patients with OAG and OHTDiscussion
This report analyzes the efficacy of primary SLT in one of
the largest datasets of treatment-naive patients with OAG
and OHT, with robust RCT-derived data. There was no
significant difference in early absolute IOP lowering be-
tween OHT and OAG eyes having controlled for pretreat-
ment baseline IOP and center effects (adjusted mean
difference ¼ 0.05 mmHg; 95% CI, 0.6 to 0.5 mmHg;
P ¼ 0.85). In addition, there was no significant difference in
early absolute IOP lowering between topical medication and
primary SLT (adjusted mean difference ¼ 0.1 mmHg,
CI, 0.6 to 0.4 mmHg, P ¼ 0.67).
We found that higher baseline IOP was a predictor of
early absolute IOP lowering at 2 months in a mixed-effects
linear regression model. Increasing baseline IOP has been
reported as being associated with increased IOP lowering3
and was also demonstrated in this study, in which OHT
eyes had greater IOP lowering from baseline compared
with OAG eyes. This is also reflected in normal-tension
glaucoma studies in which baseline IOPs are lower, and
both absolute IOP reductions and success rates are lower
compared with other subtypes.24,25 Our study design mini-
mized the effects of regression to the mean on IOP lowering:
Qualifying IOP measurements were made on a separate day
to baseline assessments, and IOP level was an entry criterionTable 11. Summary of Laser
Adverse Events during SLT Total No. of Events (n[
Discomfort (ocular or headache) 6
IOP spike (>5 mmHg) 6
Other (specify):
Fewer shots 3
Visualization of angle 5
Adverse Events Post-SLT
Total No. of Events
Total (n[172)
Discomfort (ocular or headache) 92
Blurred/altered vision 23
Change in refraction 5
Inflammation post-SLT 1
Other (specify): 51
Photophobia 21
Hyperemia 3
IOP ¼ intraocular pressure; SLT ¼ selective laser trabeculoplasty.only for OHT eyes (31.9% of eyes at baseline). There was
no placebo arm in LiGHT to ascertain fully the regression to
the mean, but a previous study has demonstrated an
approximately 1.4 mmHg (SD, 3.1) absolute IOP reduction
at the first visit after placebo compared with 5 mmHg (SD,
3.6) in the topical latanoprost group.26 We also found in our
analysis that female gender was associated with lesser initial
IOP lowering, not a commonly reported predictor of IOP
lowering.22
Our results show that at 36 months follow-up, 74.6% of
eyes (400 eyes) treated with primary SLT achieved drop-free
disease-control, with 58.2% of eyes (312 eyes) doing so after
a single initial SLT. All these eyes achieved IOP reduction
>20% from baseline IOP. Intraocular pressure reduction
>20% from baseline has been reported as occurring in be-
tween 38% and 74% of treated eyes at 36months.7,27-29 In our
study, eyes with more advanced glaucoma had to meet more
stringent target IOPs set according to previous published
guidelines: moderate or severe disease had to achieve a
minimum 30% reduction from baseline IOP to continue
without further intervention.12 Thus, more severely affected
eyes achieving >20% but <30% IOP reduction after first
SLT would have undergone a further treatment (second
SLT or medication if nonresponse to first SLT). This is
reflected in our results with only 58.2% of eyes not
receiving additional therapy. The relative proportion of eyes
achieving drop-free disease-control at 36 months after
initial single SLT at baseline (Table 7) was greater in OHT
and mild OAG eyes (with less stringent targets) than
moderate and severe OAG eyes (with lower target IOPs),
despite similar mean absolute IOP reductions for all levels
of disease severity (Table 8). This does not mean SLT was
ineffective in more advanced disease, merely insufficient in
isolation.
The above was taken into account in the predictors of
success mixed-effects logistic regression model, with terms
for baseline disease severity and site (to control for center
effects), while using the eye as the unit of analysis and using-Related Adverse Events
20) Total No. of Patients Reporting (N[19) (5.4%)
6 (1.7%)
6 (1.7%)
3 (0.9%)
4 (1.1%)
Total No. of Patients Reporting (N[122) (34.4%)
82 (23.1%)
21 (5.9%)
4 (1.1%)
1 (0.3%)
47 (13.2%)
20 (5.6%)
3 (0.8%)
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Ophthalmology Volume 126, Number 9, September 2019patients as a random factor to adjust for correlation between
paired eyes. Our logistic regression model suggested a sta-
tistically significant but small increase in odds of achieving
drop-free disease-control at 36 months with higher total
power of first SLT (adjusted odds ratio, 1.02; 95% CI,
1.01e1.04, P ¼ 0.01). On further analysis, mean total po-
wer of 1st SLT in success eyes was 92.6 mJ (SD, 21.8)
versus 87.7 mJ (SD, 25.6) in non-success eyes (adjusted
mean difference ¼ 2.37 mJ, 95% CI, 0.5 to 5.2 mJ). The
modest effect and overlap in treatment parameters between
success and non-success eyes means that response predic-
tion is not possible (Appendices 4 and 5, available at
www.aaojournal.org). The trend to a greater response with
more power delivered would need confirmation in future
studies. There is mixed evidence regarding the optimum
power settings for SLT treatment. Tang et al30 compared
39 patients receiving 100 shots of 360 SLT using low
energy settings (0.3e0.5 mJ) with 35 patients who
received 100 shots of 360 SLT using standard energy
settings (0.6e1.0 mJ). No difference in IOP lowering
between groups at all time points up to 1 year was noted.
Furthermore, there was reduced incidence of adverse
events in the lower energy group. Realini et al31 found
total laser power not to be a significant predictor of 12-
month success, with a mean (SD) of 86.0 (21.1) mJ in the
right eye and 87.7 (20.6) mJ in the left eye compared with a
mean (SD) of 90.4 (23.5) mJ in our study.8 In contrast, Lee
et al32 found that greater total SLT energy was associated
with a greater IOP lowering but this study was limited by
small sample size, short follow-up (1 month), and total
energy powers that were considerably higher than used here
(optimum total reported as 226.1 mJ). Habib et al33 divided
patients receiving 360 degree SLT treatment into those who
received low (<85 mJ), medium (85e105 mJ), or high
(>105 mJ) energy SLT. At all time points up to 36-month
follow-up, there was a significant positive correlation be-
tween greater energy and IOP lowering.33
We wanted to establish whether IOP at first scheduled
visit after SLT at 2 months was predictive of achieving
disease-control at 36 months after initial single SLT at
baseline. A previous study found that the only significant
predictor of IOP lowering at 12 months across all eyes was
time, with the maximum IOP reduction seen at 3 months
followed by a slow decline in effect subsequently.31
Although we found successful eyes achieving drop-free
disease-control after initial single SLT at 36 months had a
lower IOP at 2 months compared with non-successful eyes
(adjusted mean difference ¼ 1.9 mmHg; 95% CI, 1.4
to 2.3 mmHg), there may not be enough specificity in this
observation (because of the SD of IOP measurements) to be
helpful in the individual case.
Selective laser trabeculoplasty was well tolerated in this
study, with no sight-threatening adverse events and only 6
eyes (1% of total eyes receiving SLT) having an IOP spike
(>5 mmHg) immediately after SLT. This compares favor-
ably with other studies, which have reported IOP spikes (>5
mmHg) occurring in up to 28% of eyes.3 After SLT, 34.4%
of patients described mild laser-related adverse events,
including ocular discomfort, headache, blurred vision,
and photophobia. These were of a transient nature and1246self-limiting. Anterior chamber inflammation is common
after SLT, with up to 83% of eyes demonstrating some
degree of inflammation.34 Considering the biological
changes that SLT induces,35 some regard transient self-
limiting inflammation to be a predictable consequence of
SLT, explaining the symptoms of ocular redness, photo-
phobia, and pain that patients may report. During the
LiGHT trial overall, there were fewer drop-related
ophthalmic and systemic adverse events reported by pa-
tients in the initial SLT arm versus the initial medication
arm.13
Direct comparison between SLT studies is difficult.
Differences in study design exist between studies, including
patient demographics, disease subtypes investigated (OHT
vs. OAG), variations in topical IOP lowering medication use
before SLT (treatment-naive vs. medication washout period
before SLT vs. adjunct SLT in uncontrolled eyes on
maximum tolerated medical therapy), differences in SLT
treatment parameters (180-degree vs. 360-degree treatments,
variability in numbers of shots fired), variability in follow-
up intervals, total duration of follow-up, and variable defi-
nitions of success.
This report has several strengths. It uses data derived
from a prospective multicenter RCT with broad entry
criteria that maximize its generalizability. Eyes were treated
to predefined target IOPs based on disease severity with
predefined treatment escalation criteria and SLT treatment
parameters.12 An obvious limitation is that this analysis was
post hoc, and the sample size of LiGHT was determined on
the basis of a power calculation to analyze the primary
outcome of HRQL. We did not perform a post hoc power
calculation for the IOP-lowering parameters considered in
this report, because limitations have been reported with such
calculations.36 Instead, the narrow (<1 mmHg) CIs for our
pointwise estimates of differences in early IOP lowering
between OHT versus OAG eyes and primary SLT versus
topical medication suggest that the study had an adequate
sample size to detect a clinically important difference if it
exists.37 For our logistic regression analysis, we had
sufficient events based on the rule of thumb that 10 to 15
events per variable are required to develop an adequate
prediction model.38 In this analysis, despite no clinically
or statistically significant differences in gender or ethnicity
being noted in eyes available versus unavailable to
analyze at 36 months, relatively more female and black
patients had eyes unavailable for analysis. Studies have
shown disparities in the use of eye care services among
different racial minorities, with socioeconomic deprivation
and differences in access to healthcare implicated as
contributory to this.39,40
In conclusion, we report that primary SLT is an effective
initial therapy for treatment-naive patients with OAG and
OHT. Primary SLT provides a comparable initial IOP-
lowering response in OHT versus OAG eyes and to
topical medication. It achieves drop-free disease-control in
approximately 75% of eyes at 36 months, with the majority
of eyes (58.2%) doing so after a single initial SLT. Selective
laser trabeculoplasty had a good safety profile during our
study, while avoiding the potential adherence issues asso-
ciated with topical medication. Despite the exploratory
Garg et al  SLT in Treatment-Naive Patients with OAG and OHTnature of these analyses, our results are clinically valuable
and add to the limited body of evidence on primary SLT in
treatment-naive OAG and OHT, supporting its use as an
effective and safe initial treatment for such conditions.References
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